Form 4: Outlook Therapeutics Director Randy H. Thurman Acquires Stock Options

Director Randy H. Thurman acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Summary

• On March 7, 2024, Randy H. Thurman, a director of Outlook Therapeutics, Inc., acquired 94,441 stock options.
• The options were granted under the Issuer's 2015 Equity Incentive Plan.
• The exercise price of the options is $0.41.
• The options will fully vest on the earlier of March 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.
• The options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to continuous service immediately prior to such Change in Control.
• Following the transaction, Thurman directly owns 94,441 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent on continuous service and may be accelerated upon a Change in Control.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders.

Key Dates